Blood test could guide drug to stop transplant rejection
NCT ID NCT07025538
Summary
This study is testing if a drug called ruxolitinib can prevent a serious complication called chronic graft-versus-host disease (GVHD) in patients who have received a bone marrow transplant for blood cancer. Researchers will first use a blood test to identify patients at high risk for developing this complication. Those high-risk patients will then receive the drug for up to a year to see if it safely prevents the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.